

Figure 4. Inclusion of randomized controlled trials in systematic reviews of anti-vascular endothelial growth factor treatments for age-related macular degeneration

				Systematic reviews of anti-vascular endothelial growth factor treatments for age-related macular degeneration (n = 10)										
Randomized controlled trial (RCT) ID	Date of first publication	Interventions compared	Length of follow-up	Author Year	Takeda 2007	Colquitt 2008	Vedula 2008 (Cochrane)	Schouten 2009	Ziemsse 2009	Schmucker 2010	Schmucker 2011	Schmucker 2012	Cheng 2012	Jiang 2014
				Date of search	SEPTEMBER 2006	SEPTEMBER 2006	FEBRUARY 2008	MARCH 2008	JULY 2008	AUGUST 2009	AUGUST 2009	MAY 2011	OCTOBER 2011	MARCH 2013
				Interventions assessed	PEGAPTANIB RANIBIZUMAB	PEGAPTANIB RANIBIZUMAB	PEGAPTANIB RANIBIZUMAB	BEVACIZUMAB	BEVACIZUMAB	RANIBIZUMAB BEVACIZUMAB	RANIBIZUMAB BEVACIZUMAB	RANIBIZUMAB BEVACIZUMAB	PEGAPTANIB RANIBIZUMAB BEVACIZUMAB	RANIBIZUMAB BEVACIZUMAB
				Minimum follow-up	12 months	12 months	12 months	None	None	None	None	12 months	12 months	12 months
1. VISION	Dec 2004	Pegaptanib vs sham	> 1 year		+	+	+						+	
2. Heier	Feb 2006	Ranibizumab vs usual care	6 months							+	+			
3. MARINA	Oct 2006	Ranibizumab vs sham	> 1 year		+	+	+			+	+	+	+	+
4. ANCHOR	Oct 2006	Ranibizumab vs PDT	> 1 year		+	+	+			+	+	+	+	+
5. FOCUS	Nov 2006	Ranibizumab+PDT vs PDT	> 1 year		+	+	+			-	-	-	+	+
6. Lazic	Jan 2007	Bevacizumab vs PDT vs both	3 months					+	+	+	+			
7. Hahn	Jul 2007	Bevacizumab vs PDT+triamcinolone	3 months					+	-	+	+			
8. Bashur	Oct 2007	Bevacizumab vs PDT	6 months					+	+	+	+			
9. PIER	Feb 2008	Ranibizumab vs sham	> 1 year			+				+	+	+	+	+
10. Weigert	Mar 2008	Bevacizumab vs PDT+triamcinolone	1 year						+	+	+	+	-	-
11. SAILOR	Sep 2009	0.3 mg vs 0.5 mg ranibizumab	1 year									+		+
12. Costagliola	Dec 2009	Bevacizumab vs PDT+bevacizumab	1 year									+		-
13. Subramanian	Dec 2009	Ranibizumab vs bevacizumab	1 year									+		+
14. ABC	Jun 2010	Bevacizumab vs standard care	1 year									+	+	-
15. CATT	April 2011	Ranibizumab vs bevacizumab	> 1 year									+		+
16. Biswas	May 2011	Ranibizumab vs bevacizumab	> 1 year									+		-
17. EXCITE	May 2011	0.3 mg quarterly vs. monthly vs 0.5 mg ranibizumab	> 1 year									+		+




RCT included in the SR



RCT eligible, but not included in SR



RCT not eligible for the SR



RCT published after search date of the SR